{"ticker": {"uuid": "7b334e11-79b3-4d70-adcc-95f4a42c41b7", "symbol": "RGNX", "name": "Regenxbio Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Lawsuit alleges Regenxbio misled investors on gene therapy trial results for Hurler Syndrome.", "summary": "Kuehn Law is investigating Regenxbio, Inc. over allegations of providing false or misleading information regarding the safety and efficacy of its gene therapy trial for Hurler Syndrome. The lawsuit claims Regenxbio made overly positive statements about the trial's success based o", "url": "https://pluang.com/en/news-feed/kuehn-law-ajukan-gugatan-pemegang-saham-regenxbio", "source_name": "Pluang", "published_at": "2026-07-22T00:40:07", "published_display": "22 Jul 2026 00:40", "sentiment": "negative", "sentiment_pct": 14, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kuehn Law Encourages Investors of Regenxbio, Inc. to Contact Law Firm", "summary": "Kuehn Law, PLLC is investigating whether officers and directors of Regenxbio, Inc. (NASDAQ: RGNX) breached their fiduciary duties to shareholders. This investigation stems from a federal securities lawsuit alleging that Regenxbio provided false information regarding its RGX-111 t", "url": "https://www.morningstar.com/news/pr-newswire/20260721ny09440/kuehn-law-encourages-investors-of-regenxbio-inc-to-contact-law-firm", "source_name": "Morningstar", "published_at": "2026-07-21T23:55:07", "published_display": "21 Jul 2026 23:55", "sentiment": "negative", "sentiment_pct": 29, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 96, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Regenxbio's Gene Therapy Shows 5-Year Vision Gains in AMD", "summary": "Regenxbio reported five-year durability for its gene therapy, surabgene lomparvovec (sura-vec), showing stable to improved vision in patients with wet AMD after a single subretinal dose. These long-term results come ahead of pivotal Phase III data in Q4 2026, which will compare s", "url": "https://allsci.com/press-release/regenxbio-reports-five-year-durability-for-sura-vec-ahead-of-pivotal-wet-amd-data-%E2%AD%90/", "source_name": "AllSci", "published_at": "2026-07-20T13:10:24", "published_display": "20 Jul 2026 13:10", "sentiment": "positive", "sentiment_pct": 81, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "REGENXBIO (NASDAQ: RGNX) prices stock and warrant sale, netting $107.8M", "summary": "REGENXBIO Inc. has priced an underwritten public offering of 10,003,889 shares of common stock at $9.00 per share and 1,111,111 pre-funded warrants at $8.9999 per warrant, expecting to net approximately $107.8 million after expenses, including the full exercise of the underwriter", "url": "https://www.stocktitan.net/sec-filings/RGNX/8-k-regenxbio-inc-reports-material-event-c19052aaecb9.html", "source_name": "Stock Titan", "published_at": "2026-07-20T11:34:39", "published_display": "20 Jul 2026 11:34", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Regenxbio prices expected $100M public offering", "summary": "US biotech Regenxbio (Nasdaq: RGNX) announced the pricing of an underwritten public offering expected to raise around $100.0 million. The offering includes common stock at $9.00 per share and pre-funded warrants at $8.9999 per warrant. Following the announcement, the company's sh", "url": "https://www.thepharmaletter.com/biotech-news/regenxbio-prices-expected-100m-public-offering", "source_name": "The Pharma Letter", "published_at": "2026-07-20T11:10:39", "published_display": "20 Jul 2026 11:10", "sentiment": "negative", "sentiment_pct": 40, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "REGENXBIO Presents Positive Long-Term Data for Surabgene Lomparvovec in Wet AMD and Diabetic Retinopathy at American Society of Retina Specialists Annual Meeting", "summary": "REGENXBIO Inc. announced positive long-term data for its investigational gene therapy, surabgene lomparvovec (sura-vec), for wet Age-related Macular Degeneration (AMD) and diabetic retinopathy (DR). The data, presented at the ASRS Annual Meeting, showed durable efficacy and safet", "url": "https://www.prnewswire.com/news-releases/regenxbio-presents-positive-long-term-data-for-surabgene-lomparvovec-in-wet-amd-and-diabetic-retinopathy-at-american-society-of-retina-specialists-annual-meeting-302828998.html", "source_name": "PR Newswire", "published_at": "2026-07-19T01:10:10", "published_display": "19 Jul 2026 01:10", "sentiment": "positive", "sentiment_pct": 74, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Five-Year Wet AMD Follow-Up Reports Stable-to-Improved Vision", "summary": "REGENXBIO announced positive long-term data for its investigational gene therapy, surabgene lomparvovec (sura-vec), for wet age-related macular degeneration (wet AMD) and diabetic retinopathy (DR) at the ASRS 2026 meeting. Five-year data for wet AMD showed stable to improved visu", "url": "https://www.stocktitan.net/news/RGNX/regenxbio-presents-positive-long-term-data-for-surabgene-lomparvovec-l8tja71qww7k.html", "source_name": "Stock Titan", "published_at": "2026-07-18T18:40:27", "published_display": "18 Jul 2026 18:40", "sentiment": "positive", "sentiment_pct": 70, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "REGENXBIO Stock Slides After $100M Equity Offering Pricing", "summary": "REGENXBIO Inc. (RGNX) stock dropped over 11% after pricing a $100 million equity and pre-funded warrant offering at $9.00 per share. This offering, intended to fund its late-stage gene therapy pipeline, has raised concerns about dilution and near-term selling pressure. The compan", "url": "https://timothysykes.com/news/regenxbioinc-rgnx-news-2026_07_18/", "source_name": "timothysykes.com", "published_at": "2026-07-18T14:11:23", "published_display": "18 Jul 2026 14:11", "sentiment": "negative", "sentiment_pct": 20, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "REGENXBIO Stock Slides After $100M Equity Offering Shock", "summary": "REGENXBIO Inc. (RGNX) stock dropped by 11.92% after announcing a $100 million public offering of common stock and pre-funded warrants at $9.00 per share to fund operations and pipeline development. This equity raise, coupled with a shareholder litigation firm investigating allege", "url": "https://stockstotrade.com/news/regenxbioinc-rgnx-news-2026_07_18/", "source_name": "StocksToTrade", "published_at": "2026-07-18T12:11:23", "published_display": "18 Jul 2026 12:11", "sentiment": "negative", "sentiment_pct": 19, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "REGENXBIO (NASDAQ: RGNX) launches $100M equity and pre-funded warrant raise", "summary": "REGENXBIO Inc. (NASDAQ: RGNX) is conducting a primary offering of 10,003,889 shares of common stock and 1,111,111 pre-funded warrants for a total public offering price of $100 million. The public offering price is $9.00 per share and $8.9999 per warrant, with underwriters having ", "url": "https://www.stocktitan.net/sec-filings/RGNX/424b5-regenxbio-inc-prospectus-supplement-debt-securities-2a43cf019f26.html", "source_name": "Stock Titan", "published_at": "2026-07-17T21:09:29", "published_display": "17 Jul 2026 21:09", "sentiment": "negative", "sentiment_pct": 33, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Regenxbio (RGNX) Launches $100 Million Public Offering", "summary": "Regenxbio Inc. (RGNX) announced a public offering of common stock and pre-funded warrants aimed at raising approximately $100 million to support its gene therapy research and development. The company, which has a market cap of $579.01 million, has a GF Score of 60, indicating mod", "url": "https://www.gurufocus.com/news/8964468/regenxbio-rgnx-launches-100-million-public-offering?utm_source=marketwatch&utm_medium=syndication&utm_campaign=headlines&r=4bf001661e6fdd88d0cd7a5659ff9748&mod=mw_quote_news", "source_name": "GuruFocus", "published_at": "2026-07-17T20:10:53", "published_display": "17 Jul 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RGNX Stock Slides As $100M Offering And Legal Heat Hit", "summary": "REGENXBIO Inc. (RGNX) stock is down over 9% following news of a planned $100 million public offering of common stock and a pending investigation into its officers and directors over alleged misleading statements related to a gene therapy trial. The offering aims to fund its late-", "url": "https://stockstotrade.com/news/regenxbio-inc-rgnx-news-2026_07_17/", "source_name": "StocksToTrade", "published_at": "2026-07-17T18:09:29", "published_display": "17 Jul 2026 18:09", "sentiment": "negative", "sentiment_pct": 15, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Regenxbio Shares Fall on $100M Stock, Pre-Funded Warrant Offering", "summary": "Regenxbio (RGNX) announced a public offering of $100 million in common stock and pre-funded warrants. This financial move led to a significant 10% decline in the company's shares during after-hours trading. The offering includes standard stock and warrants, which can be exercised", "url": "https://www.moomoo.com/news/post/73153805/regenxbio-shares-fall-on-100m-stock-pre-funded-warrant-offering?futusource=news_newspage_recommend", "source_name": "Moomoo", "published_at": "2026-07-17T15:10:53", "published_display": "17 Jul 2026 15:10", "sentiment": "negative", "sentiment_pct": 29, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "REGENXBIO Raises $100M for Gene Therapy Pipeline", "summary": "REGENXBIO Inc. (Nasdaq: RGNX) announced a proposed underwritten public offering to raise $100 million for its gene therapy pipeline. This funding comes as the company advances multiple late-stage programs, including RGX-202 for Duchenne muscular dystrophy and RGX-121 for Hunter s", "url": "https://allsci.com/news/funding/public-equity-offerings/regenxbio-raises-usd-100m-amid-pivotal-year-for-gene-therapy-pipeline/", "source_name": "AllSci", "published_at": "2026-07-17T15:09:29", "published_display": "17 Jul 2026 15:09", "sentiment": "positive", "sentiment_pct": 63, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RGNX Stock Dips As Equity Offering And Litigation Raise Risk", "summary": "REGENXBIO Inc. (RGNX) stock experienced a significant dip due to a bearish sentiment following a planned $100M public offering of common stock and ongoing shareholder litigation. The equity offering aims to fund its late-stage gene therapy pipeline but introduces dilution, while ", "url": "https://timothysykes.com/news/regenxbio-inc-rgnx-news-2026_07_17/", "source_name": "timothysykes.com", "published_at": "2026-07-17T15:09:29", "published_display": "17 Jul 2026 15:09", "sentiment": "negative", "sentiment_pct": 30, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "REGENXBIO Prices $100 Million Public Offering", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/regenxbio-prices-100-million-public-112412501.html", "source_name": "MT Newswires", "published_at": "2026-07-17T11:24:12+00:00", "published_display": "17 Jul 2026 11:24", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "REGENXBIO Announces Pricing of Public Offering of Common Stock and Pre-funded Warrants", "summary": "REGENXBIO Inc. has announced the pricing of a public offering consisting of 10,003,889 shares of common stock at $9.00 per share and 1,111,111 pre-funded warrants at $8.9999 per warrant. The offering is expected to generate approximately $100.0 million in gross proceeds and is sl", "url": "https://www.prnewswire.com/news-releases/regenxbio-announces-pricing-of-public-offering-of-common-stock-and-pre-funded-warrants-302828273.html", "source_name": "PR Newswire", "published_at": "2026-07-17T11:09:29", "published_display": "17 Jul 2026 11:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Regenxbio prices $100m public offering at $9 per share", "summary": "REGENXBIO Inc. has priced an underwritten public offering of common stock and pre-funded warrants at $9 per share, aiming to raise approximately $100.0 million. This capital raise comes after a nearly 20% stock decline and a reported negative free cash flow of $236 million over t", "url": "https://www.investing.com/news/company-news/regenxbio-prices-100m-public-offering-at-9-per-share-93CH-4798047", "source_name": "Investing.com", "published_at": "2026-07-17T11:09:29", "published_display": "17 Jul 2026 11:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "REGENXBIO (RGNX) Launches $100M Public Offering at $9.00 per Sha", "summary": "REGENXBIO (RGNX) announced a $100 million public offering of common shares at $9.00 each and pre-funded warrants, aiming to raise capital for its gene therapy development despite a premarket stock decline. The company has a GF Score\u2122 of 60/100, showing moderate potential for long", "url": "https://www.gurufocus.com/news/8964529/regenxbio-rgnx-launches-100m-public-offering-at-900-per-share?utm_source=marketwatch&utm_medium=syndication&utm_medium=syndication&utm_campaign=headlines&utm_campaign=headlines&r=4bf001661e6fdd88d0cd7a5659ff9748&r=4bf001661e6fdd88d0cd7a5659ff9748&mod=mw_quote_news%3Futm_source%3Dmarketwatch&mod=mw_quote_news&mobile=true", "source_name": "GuruFocus", "published_at": "2026-07-17T07:00:00", "published_display": "17 Jul 2026 07:00", "sentiment": "negative", "sentiment_pct": 28, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "REGENXBIO (RGNX) Plans $100 Million Stock Offering Amid Market D", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxObE9xcGRucU5TT3lPMjB5Z1lRWDh1dDQ3QXBJeE43czREMmtuem42S3RHY0xwMGhUMDBfaTZjQzhNSjlBWURfVk05dnNqbEZwVHJjVFpqQ255T2VnbmxBUEV6SGJ6RElQZllKcHZuM0RnSmhDMk5TWVRDTnUzdDhnVlJYeWx6VTB2YkRnZngwRF9aWkwzOEVISVE0b1FiMWVPSzJTbFp3WjB4Zkh6Und3bnFlSnE?oc=5", "source_name": "GuruFocus", "published_at": "2026-07-17T00:56:15+00:00", "published_display": "17 Jul 2026 00:56", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RGNX Stock Slumps 15% After-Hours \u2014 What\u2019s Driving The Selloff?", "summary": "REGENXBIO Inc. (RGNX) shares dropped 15% after-hours following the announcement of a $100 million public stock offering, sparking dilution concerns among investors. The company, which specializes in gene therapies for rare diseases, has not specified how the new funds will be uti", "url": "https://www.tradingview.com/news/stocktwits:054b88e0e094b:0-rgnx-stock-slumps-15-after-hours-what-s-driving-the-selloff/", "source_name": "TradingView", "published_at": "2026-07-16T22:42:41", "published_display": "16 Jul 2026 22:42", "sentiment": "negative", "sentiment_pct": 29, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "REGENXBIO Announces Proposed $100 Million Public Stock Offering", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/regenxbio-announces-proposed-100-million-203808250.html", "source_name": "MT Newswires", "published_at": "2026-07-16T20:38:08+00:00", "published_display": "16 Jul 2026 20:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "REGENXBIO\u2019s Proposed $100M Stock Sale Has No Set Terms", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNaS1jWHNWQ0Q0dXAwZVQ0U1NpYVdEMUtEa19Yc2Q4TVBOVERscDgwYnpUTUViSUtUUTNFb0prb1lyMmRuRlhGa2ZLVW84TWt2cUhJV3NJYmJTY09ZUGJMSlNhV2JqMEF4MkFORzgwWXVVSk9qeXdxdl9WNVNVWHlUd1AtT3NrNDAtUU4yZnI2NlJfMDlkanJBME5TaENYM09sMy1YZWVOR1JoTzFCQ1E?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-16T20:26:00+00:00", "published_display": "16 Jul 2026 20:26", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "REGENXBIO (NASDAQ: RGNX) targets $100M stock sale to fund gene therapy", "summary": "REGENXBIO Inc. (NASDAQ: RGNX) plans a primary offering of $100 million in common stock to fund general corporate purposes, including clinical trials and pipeline development. The company anticipates receiving a $100 million milestone payment from AbbVie in July 2026 and expects i", "url": "https://www.stocktitan.net/sec-filings/RGNX/424b5-regenxbio-inc-prospectus-supplement-debt-securities-defcdb940e16.html", "source_name": "Stock Titan", "published_at": "2026-07-16T20:40:04", "published_display": "16 Jul 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "REGENXBIO files prospectus for up to $100M common stock offering", "summary": "REGENXBIO has filed a prospectus with the SEC for a common stock offering that could raise up to $100 million. The filing is a standard procedure that allows the company flexibility in future fundraising efforts. This move indicates potential plans to finance ongoing operations, ", "url": "https://www.msn.com/en-us/money/general/regenxbio-files-prospectus-for-up-to-100m-common-stock-offering/ar-AA284R7c?ocid=finance-verthp-feeds", "source_name": "MSN", "published_at": "2026-07-16T20:40:04", "published_display": "16 Jul 2026 20:40", "sentiment": "negative", "sentiment_pct": 39, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Regenxbio plans $100 million common stock offering", "summary": "REGENXBIO Inc. (NASDAQ:RGNX) announced a $100 million public offering of common stock, which will be underwritten by Morgan Stanley, J.P. Morgan, Leerink Partners, and Mizuho. The company, focused on gene therapy for rare and retinal diseases, is rapidly burning through cash, wit", "url": "https://www.investing.com/news/company-news/regenxbio-plans-100-million-common-stock-offering-93CH-4796837", "source_name": "Investing.com", "published_at": "2026-07-16T20:40:04", "published_display": "16 Jul 2026 20:40", "sentiment": "negative", "sentiment_pct": 38, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "REGENXBIO Announces Proposed Public Offering of Common Stock", "summary": "REGENXBIO Inc. announced its intention to offer and sell $100 million of its common stock in an underwritten public offering, contingent on market conditions. The company also plans to grant underwriters a 30-day option to purchase up to an additional 15% of the shares offered. M", "url": "https://www.prnewswire.com/news-releases/regenxbio-announces-proposed-public-offering-of-common-stock-302827988.html", "source_name": "PR Newswire", "published_at": "2026-07-16T20:40:04", "published_display": "16 Jul 2026 20:40", "sentiment": "negative", "sentiment_pct": 35, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "RGNX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Reminds Stockholders of REGENXBIO Inc. to Contact the Firm Today!", "summary": "Bronstein, Gewirtz and Grossman, LLC has filed a class action lawsuit against REGENXBIO Inc. (NASDAQ: RGNX) and its officers. The lawsuit alleges that REGENXBIO made false and misleading statements regarding its gene therapy RGX\u2011111 for treating Hurler syndrome. Investors who pur", "url": "https://natlawreview.com/press-releases/rgnx-investor-alert-bronstein-gewirtz-and-grossman-llc-reminds-1", "source_name": "The National Law Review", "published_at": "2026-07-15T08:11:16", "published_display": "15 Jul 2026 08:11", "sentiment": "negative", "sentiment_pct": 9, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T07:00:00+00:00", "published_display": "13 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Regenxbio | 8-K: Current report", "summary": "This document is an 8-K current report filed by Regenxbio. It is a standard regulatory filing used to announce material events that shareholders should know about.", "url": "https://www.moomoo.com/news/notice/307458163/regenxbio-8-k-current-report", "source_name": "Moomoo", "published_at": "2026-07-12T19:40:20", "published_display": "12 Jul 2026 19:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RegenxBio doses first patient in phase 2b/3 trial for DR", "summary": "RegenxBio has dosed the first patient in its phase 2b/3 NAAVIGATE trial for surabgene lomparvovec (sura-vec, ABBV-RGX-314) for diabetic retinopathy (DR) using suprachoroidal delivery. This gene therapy, developed in partnership with AbbVie, utilizes RegenxBio's proprietary NAV Te", "url": "https://glance.eyesoneyecare.com/stories/2026-07-10/regenxbio-doses-first-patient-in-phase-2b-3-trial-for-dr/", "source_name": "Eyes On Eyecare", "published_at": "2026-07-10T17:40:10", "published_display": "10 Jul 2026 17:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "(RGNX) Movement as an Input in Quant Signal Sets", "summary": "This article from Stock Traders Daily analyzes Regenxbio Inc. (NASDAQ: RGNX) using AI models, identifying strong near and mid-term sentiment but a weak long-term outlook. It provides specific institutional trading strategies (Position, Momentum Breakout, Risk Hedging) with entry ", "url": "https://news.stocktradersdaily.com/news_release/98/RGNX_Movement_as_an_Input_in_Quant_Signal_Sets_070926044001_1783629601.html", "source_name": "Stock Traders Daily", "published_at": "2026-07-09T16:10:49", "published_display": "09 Jul 2026 16:10", "sentiment": "positive", "sentiment_pct": 66, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Regenxbio Inc outlines gene therapy pipeline as Nasdaq-listed biotech stays focused on long-term gro", "summary": "Regenxbio Inc. is a Nasdaq-listed gene therapy company focusing on long-term growth through its clinical pipeline and licensing model in rare diseases and ophthalmology. The company utilizes proprietary AAV vector technology to develop gene therapies designed for durable treatmen", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/regenxbio-inc-outlines-gene-therapy-pipeline-as-nasdaq-listed-biotech/69715973", "source_name": "AD HOC NEWS", "published_at": "2026-07-07T16:42:17", "published_display": "07 Jul 2026 16:42", "sentiment": "positive", "sentiment_pct": 81, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Regenxbio Insider Sold Shares Worth $688,756, According to a Recent SEC Filing", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/regenxbio-insider-sold-shares-worth-082648885.html", "source_name": "MT Newswires", "published_at": "2026-07-02T08:26:48+00:00", "published_display": "02 Jul 2026 08:26", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Proposed 43,206-share sale for RGNX (NASDAQ: RGNX) tied to option exercise", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxQTXF6QmJDTzEwU2l3UmszS01QOElES1ZyNWNoYkIzRUNMbDNfbWR2eWp3OWp5NTFYSWNFaEQ2ekcxQ2xTM0EyS1pGTzQ1TmRVa0FSYl81RHZScXZzY2VWUno4cE1CaFRoYlRtNTVHUzM5aHJTV3NUbzRrSUNnR24wTXduLTRyN20taEIyOUdLeWRHM3ZX?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-01T07:00:00+00:00", "published_display": "01 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "REGENXBIO's Trial of Surabgene Lomparvovec in Diabetic Retinopathy Doses First Patient", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/regenxbio-apos-trial-surabgene-lomparvovec-120939541.html", "source_name": "MT Newswires", "published_at": "2026-06-29T12:09:39+00:00", "published_display": "29 Jun 2026 12:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "REGENXBIO doses first patient in eye-disease gene therapy trial", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxNM1Z4dUh0U1R1MmNaYW9zd3VlVWF6QjVQb3BsVGVzMG1wa19UTTBISk9LaU4ycE5halJsZ011WTE2dmQ2LWtyQkpweXpKOWpMYzZkeUFvVVRnSlA2TDRnT19hajJsZnplaUh3eUFxcHlNZWY5RmIxQWFKeWp2ZklucEdmdjczanVlSGVtRmJvVWcyTWZTaWlJY1JZMHczT182Vlk5ZWtvZW9TNDdzSFBpSXlpUV84SFBvY2F3aXBMYw?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-29T07:00:00+00:00", "published_display": "29 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "REGENXBIO clears key Duchenne study step, aims for BLA filing in Q3", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxQNUpwRjNhRm5ZUWpNN0dRcG9FeEhYcjluNDR4SG1MWUppUDNESTZQeGVrX0F0THU3ejk3VzZDTG9BLUtJT2RPS3dnQmlFU1lNanRSQlNQZkNqdmZuVWFySk1PWjd5WHpRWjdyRmJHZUIteFFGWTBUWktNUUhybHQ1d2NZQ04xdURjUGsxRFI1cWIyM25yVTZWQVZkX1hRWEtrdnRBMkpmN29rYTBWaFcwT09jNExWdm01T0xadVFZSQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-24T07:00:00+00:00", "published_display": "24 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H.C. Wainwright reiterates Regenxbio stock rating on FDA pathway", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxOR3NhbDQyTEZ4eUI0cG9ndkswZmhBTi1jYktuSzJzZFd5eEcza0tHTm5GQ0UzallVaE9jaTJoQlF5WTVZV1JjcXdRTWNmRXRUXzJDb2xBSS0wQTNmaGNpYjd0el9KNnVMdjN1ZlVCMnE1SGdTbVVFV1ctSUNIV19Bd1NGb2FLb0pEcTlBRWNpY043OTc5SWYycjlnUXFWS2lPc1Zkb01KdmtsT1hVbk9pWWdybU5lNFg1NDg4d0N4aw?oc=5", "source_name": "Investing.com", "published_at": "2026-06-23T07:00:00+00:00", "published_display": "23 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "REGENXBIO gets FDA path to resubmit NAVSUNLI for MPS II", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxOcGxveGdJWUp6RGNwS1hRemRZaTdSNmViM0RDMF90NHlSWWxOZ0I3a1dFdlJEWFNpelZyWm1NdTVDd2lEaVNwWTlyTk5DeTd6STJCcERUNlAzS0JGcFpCejlrcC1mbVNuVlhrcnZPRFo0UFlWWU1SeHN6NHUxMDB4ZGpqQU5MdWE4U2hqSWdNNWN2TzdiSl9xUUxMSTRKS2czNWFfRExjTFVuT2EtWnlocUlDTQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-22T07:00:00+00:00", "published_display": "22 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RGNX Retail Investors See Hope As FDA Reopens Door For Regenxbio\u2019s Hunter Syndrome Therapy", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwgFBVV95cUxPTGVWVkt4b3NZMFlvbHcyc3VJNE5qWkE0UGdyWjRRV0ZYVk1DSm00ckotd1VIQ25qVlZhZm9lSHJNU3diTFBPaHRBZzdSRXpiTGFUaHJoVFJSU1hLcEZVZkhaNjc4a0szWFBFN1lfNk1Zb2JKWTYyN09ocEw2YnMzZmZXUDhrT0pCWWtoU3JRVlZXUDhBWE4zVGpiZzB5ZkN5Z0ZPaFVuemZHdk5CSjQzRUVtemJORXFGWXpWa2RWQVhOdw?oc=5", "source_name": "Stocktwits", "published_at": "2026-06-22T07:00:00+00:00", "published_display": "22 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "JPMorgan affiliates report 4.4% stake in REGENXBIO (RGNX) in 13G/A", "summary": "", "url": "https://news.google.com/rss/articles/CBMixwFBVV95cUxQOW0tSFNtTFhIYnpTRXRxVE9GVkFwekFqRldVT244ZWxacWxoMlhKeW5UOG10YWFLemVrZ05VeVZncjByZFRYU3BlNk41Q0FFOUlxWUN1LTdsN3N1Q1ktSVAxNThra1kxY3h6MXdhdnc0N1M4N0ZjR1Z5dkgxVTloeFc0TXI1czhiQ1pNQWkwaU1hbmRQZDQxMGQ1ZXNiVXRTaklrSmNhdXdpaWlwXzFiOGVJV0tYaG42b2NfcjdZYTIzTEJQODZN?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-04T07:00:00+00:00", "published_display": "04 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Before Buying Regenxbio Inc (RGNX) Stock, Check Out the Cash Runway", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxQX2c4M0RLM2NtTnBJM1AzRGdMOUROUkR4SURJbW96YjVESTlLVWNYV3VHNTRXUmFjc3hfMXNUSkhIU2hyYkJkb3QwYzFrWWdaaGhrSi1nZV9paEFRSFpURS1udEQ0THlESkpvakw4RXN4X2pxTzMxRHpPTldEQkFQaVBvSWNyVmkzMkFVc2s4MnZtcVFJcVFseXdvQVZua2xrNWc?oc=5", "source_name": "Market source", "published_at": "2026-05-20T07:00:00+00:00", "published_display": "20 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "StockWatch: Regenxbio Tumbles Despite Positive Pivotal Data for DMD Gene Therapy Candidate", "summary": "", "url": "https://news.google.com/rss/articles/CBMi4AFBVV95cUxPZkp0VzdkNVVCV0NTejgyeUs5emJBczlDcmZNRDZaSzQ2YXFuQ1diNnpLSE9oMmY0UHZSNllUY25rX0huN3ZNZEZUY2JUUDZ2Y2NCczJ1MlJLZ2RNVDU3OU1TM3RmVjhmQWxlcXppM3FpVFltTmxKTkxuWU8waVRON01IOTJoSHlLSW1BMDFvNjItZDVmTjF3N29MVmpaQlpyY0ZVUHdFSWhuTGtLNFY4RlFnVUFMaHItbEtpZzJHV1BkT1B5bVBmSmdwYmtxbmJTZ2RPTkoyRm01Y2hxUkE4Qg?oc=5", "source_name": "Genetic Engineering and Biotechnology News", "published_at": "2026-05-17T07:00:00+00:00", "published_display": "17 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Goldman Sachs lowers Regenxbio stock price target on regulatory uncertainty", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0AFBVV95cUxQMUlpamVaN0x0TkVqTFhIWHNubWJQa050VXJZZWU2T2p0bVhJb1pCT2lERTFIclFlZ0tzMFZVRl9vcnAtOGt5TE5mZFdHUjdZaEFGeDhYdVRkaV9HU0NtSGNsTzhTVk1CRFlIS2RldWZieVlNalpOdXd3Tmd2WWp0VVZydlZJQktsMVZPUzZTWTEtUjZEUE5ubkg4bjlxQm9tWmN3LWpZVlc1STRkeVJKdkRDV0EwSXVPcGY0YmdmVW1lNE1WUFpwTmZaSGxaY3dU?oc=5", "source_name": "Investing.com", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Regenxbio (RGNX) Q1 Loss Deepens And Reinforces Bearish Cash Runway Concerns", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 18, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Why is Regenxbio stock plunging today?", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxPRnh6MTZXYzlRQk1BVEZJVmZMNnJ0ak02TVBRU1piT0dScHNYRFJkQXpfR3o4WGpqcVZZaU5ybEtmNUItOVVqdTctUGo5bzAzaEFUYjFkLXU4QWYxSEZxNUYzOTlXNE03ajJOWHZwbzhjeVhvblZlU3N1dEpxSjB4bEpXbTFnSFdlYW1iSGlQTGRfZnFDcDBrMU54amFlUG5E?oc=5", "source_name": "Investing.com", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Duchenne gene therapy clears Phase III goal as REGENXBIO posts $90M loss", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxNVDdZQnB1WU83Y21rdDdyeDJXQTBWdUpYS0tTU1ROV3FCdU5MV0w2bnZjMGtBMk9uaEROUW81SElSSmtDU1JaeXRuN3kza0txeHlMajE2NHM0c3Uzc2FkTERxZllzdC1NQm5wUUR5WFhLT2Y3S2ZCUzFROVlkR3FVTnJ1R1E4SWwzdFBBMTlQNjVtOVpqMHhfdFczN3M5TGlLdjRjV0gxaDE3QUZfVWQ1OVl6aw?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Sarepta Hits Fresh Hurdle As Court Revives Patent Lawsuit With Regenxbio Over Muscular Disorder Therapy", "summary": "", "url": "https://news.google.com/rss/articles/CBMi-wFBVV95cUxPbnpwWDJhbVdjOTZVODduRkNOVVAxYVBRUXUtY200cUNMMzV1U2dWSEV6NThyMTFmSDRWRHRuWUdMZ2Z3MWx2NU14YV9lak03SDNERnVacjFNR092S2xsTzdqT1VNaXFfdi1POVBIbXpaUThINkc4S3lKVXlLT1dGLU5qbG1ZQ05DSFVfMXlLQzRDWEY3dTlaaWxaQUJ4ZHVxdUxhd1VOOFlBNVhTdW1qVEZXWEZncmM0Y01heGRHM2VDb0ZfeHg3d1M3eTJJaFRfR09uV0xPaUhKRHp2bVNIOHZEektibVJqQ19yRFFTSnZ0ZXh5UXh0S0ZWYw?oc=5", "source_name": "Stocktwits", "published_at": "2026-02-20T22:04:27+00:00", "published_display": "20 Feb 2026 22:04", "sentiment": "negative", "sentiment_pct": 34, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Regenxbio Stock Still Has Over 300% Upside Despite FDA Pushback On Hunter Syndrome Drug: Clear Street", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1AFBVV95cUxPbV9MNHF1YWpfZlpoRmpLVjRrWWFWQXNSOUdTWEhuajhFa2haY3lIUHJjSkhuVm03WlpmdDVobmtoU2ZDNV9Qa21CRE1VdWhaTDBfeWl6Wjg3TG5tV2trTGc0ODBBcEt2eWpWWHprREx4a3UwVlBUTHVXanBqRjRhZ2xwbEJLSXp2dUJXZlFFNFBzemJkUUdkYzJsbmNPY09ISjhVeENtZFVGa0JEYVpLWkRSaW1RLUVTNFc3MkRXaElDNk1wNE0ycmdaMzk1TjljZVN1bg?oc=5", "source_name": "Stocktwits", "published_at": "2026-02-09T08:00:00+00:00", "published_display": "09 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "US FDA declines to approve Regenxbio's gene therapy for rare disease", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwgFBVV95cUxQOERkNXNGX05jeWdQNWFrTFpCcW0yWDFKUlZLaFFRX2J0UHpxRTk4SVdaOUdlOS11WUF3Q2xHOEloU2JvUUFvUGhJb283TmV2Tm9SRkdpRTNNSzRpdVNZU3E4MG5IdDl5Zk9USTR3X1JFZTlXTFlBR2NKZVBvM28yVjcwOVZZdjBtTDhZMENkUmVldm9vclAxNFg4UmQ0WWdTWnFLR3NzVGRuZlRVTmNYVjlkdW1LcHg3MF94V0kzdWpXQQ?oc=5", "source_name": "Reuters", "published_at": "2026-02-09T08:00:00+00:00", "published_display": "09 Feb 2026 08:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "REGENXBIO Inc. (NASDAQ:RGNX) Looks Inexpensive After Falling 28% But Perhaps Not Attractive Enough", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-02-06T08:00:00+00:00", "published_display": "06 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Lawsuit alleges Regenxbio misled investors on gene therapy trial results for Hurler Syndrome.", "summary": "Kuehn Law is investigating Regenxbio, Inc. over allegations of providing false or misleading information regarding the safety and efficacy of its gene therapy trial for Hurler Syndrome. The lawsuit claims Regenxbio made overly positive statements about the trial's success based o", "url": "https://pluang.com/en/news-feed/kuehn-law-ajukan-gugatan-pemegang-saham-regenxbio", "source_name": "Pluang", "published_at": "2026-07-22T00:40:07", "published_display": "22 Jul 2026 00:40", "sentiment": "negative", "sentiment_pct": 14, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kuehn Law Encourages Investors of Regenxbio, Inc. to Contact Law Firm", "summary": "Kuehn Law, PLLC is investigating whether officers and directors of Regenxbio, Inc. (NASDAQ: RGNX) breached their fiduciary duties to shareholders. This investigation stems from a federal securities lawsuit alleging that Regenxbio provided false information regarding its RGX-111 t", "url": "https://www.morningstar.com/news/pr-newswire/20260721ny09440/kuehn-law-encourages-investors-of-regenxbio-inc-to-contact-law-firm", "source_name": "Morningstar", "published_at": "2026-07-21T23:55:07", "published_display": "21 Jul 2026 23:55", "sentiment": "negative", "sentiment_pct": 29, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 96, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Regenxbio's Gene Therapy Shows 5-Year Vision Gains in AMD", "summary": "Regenxbio reported five-year durability for its gene therapy, surabgene lomparvovec (sura-vec), showing stable to improved vision in patients with wet AMD after a single subretinal dose. These long-term results come ahead of pivotal Phase III data in Q4 2026, which will compare s", "url": "https://allsci.com/press-release/regenxbio-reports-five-year-durability-for-sura-vec-ahead-of-pivotal-wet-amd-data-%E2%AD%90/", "source_name": "AllSci", "published_at": "2026-07-20T13:10:24", "published_display": "20 Jul 2026 13:10", "sentiment": "positive", "sentiment_pct": 81, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "REGENXBIO (NASDAQ: RGNX) prices stock and warrant sale, netting $107.8M", "summary": "REGENXBIO Inc. has priced an underwritten public offering of 10,003,889 shares of common stock at $9.00 per share and 1,111,111 pre-funded warrants at $8.9999 per warrant, expecting to net approximately $107.8 million after expenses, including the full exercise of the underwriter", "url": "https://www.stocktitan.net/sec-filings/RGNX/8-k-regenxbio-inc-reports-material-event-c19052aaecb9.html", "source_name": "Stock Titan", "published_at": "2026-07-20T11:34:39", "published_display": "20 Jul 2026 11:34", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Regenxbio prices expected $100M public offering", "summary": "US biotech Regenxbio (Nasdaq: RGNX) announced the pricing of an underwritten public offering expected to raise around $100.0 million. The offering includes common stock at $9.00 per share and pre-funded warrants at $8.9999 per warrant. Following the announcement, the company's sh", "url": "https://www.thepharmaletter.com/biotech-news/regenxbio-prices-expected-100m-public-offering", "source_name": "The Pharma Letter", "published_at": "2026-07-20T11:10:39", "published_display": "20 Jul 2026 11:10", "sentiment": "negative", "sentiment_pct": 40, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "REGENXBIO Presents Positive Long-Term Data for Surabgene Lomparvovec in Wet AMD and Diabetic Retinopathy at American Society of Retina Specialists Annual Meeting", "summary": "REGENXBIO Inc. announced positive long-term data for its investigational gene therapy, surabgene lomparvovec (sura-vec), for wet Age-related Macular Degeneration (AMD) and diabetic retinopathy (DR). The data, presented at the ASRS Annual Meeting, showed durable efficacy and safet", "url": "https://www.prnewswire.com/news-releases/regenxbio-presents-positive-long-term-data-for-surabgene-lomparvovec-in-wet-amd-and-diabetic-retinopathy-at-american-society-of-retina-specialists-annual-meeting-302828998.html", "source_name": "PR Newswire", "published_at": "2026-07-19T01:10:10", "published_display": "19 Jul 2026 01:10", "sentiment": "positive", "sentiment_pct": 74, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Five-Year Wet AMD Follow-Up Reports Stable-to-Improved Vision", "summary": "REGENXBIO announced positive long-term data for its investigational gene therapy, surabgene lomparvovec (sura-vec), for wet age-related macular degeneration (wet AMD) and diabetic retinopathy (DR) at the ASRS 2026 meeting. Five-year data for wet AMD showed stable to improved visu", "url": "https://www.stocktitan.net/news/RGNX/regenxbio-presents-positive-long-term-data-for-surabgene-lomparvovec-l8tja71qww7k.html", "source_name": "Stock Titan", "published_at": "2026-07-18T18:40:27", "published_display": "18 Jul 2026 18:40", "sentiment": "positive", "sentiment_pct": 70, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "REGENXBIO Stock Slides After $100M Equity Offering Pricing", "summary": "REGENXBIO Inc. (RGNX) stock dropped over 11% after pricing a $100 million equity and pre-funded warrant offering at $9.00 per share. This offering, intended to fund its late-stage gene therapy pipeline, has raised concerns about dilution and near-term selling pressure. The compan", "url": "https://timothysykes.com/news/regenxbioinc-rgnx-news-2026_07_18/", "source_name": "timothysykes.com", "published_at": "2026-07-18T14:11:23", "published_display": "18 Jul 2026 14:11", "sentiment": "negative", "sentiment_pct": 20, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "REGENXBIO Stock Slides After $100M Equity Offering Shock", "summary": "REGENXBIO Inc. (RGNX) stock dropped by 11.92% after announcing a $100 million public offering of common stock and pre-funded warrants at $9.00 per share to fund operations and pipeline development. This equity raise, coupled with a shareholder litigation firm investigating allege", "url": "https://stockstotrade.com/news/regenxbioinc-rgnx-news-2026_07_18/", "source_name": "StocksToTrade", "published_at": "2026-07-18T12:11:23", "published_display": "18 Jul 2026 12:11", "sentiment": "negative", "sentiment_pct": 19, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "REGENXBIO (NASDAQ: RGNX) launches $100M equity and pre-funded warrant raise", "summary": "REGENXBIO Inc. (NASDAQ: RGNX) is conducting a primary offering of 10,003,889 shares of common stock and 1,111,111 pre-funded warrants for a total public offering price of $100 million. The public offering price is $9.00 per share and $8.9999 per warrant, with underwriters having ", "url": "https://www.stocktitan.net/sec-filings/RGNX/424b5-regenxbio-inc-prospectus-supplement-debt-securities-2a43cf019f26.html", "source_name": "Stock Titan", "published_at": "2026-07-17T21:09:29", "published_display": "17 Jul 2026 21:09", "sentiment": "negative", "sentiment_pct": 33, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Regenxbio (RGNX) Launches $100 Million Public Offering", "summary": "Regenxbio Inc. (RGNX) announced a public offering of common stock and pre-funded warrants aimed at raising approximately $100 million to support its gene therapy research and development. The company, which has a market cap of $579.01 million, has a GF Score of 60, indicating mod", "url": "https://www.gurufocus.com/news/8964468/regenxbio-rgnx-launches-100-million-public-offering?utm_source=marketwatch&utm_medium=syndication&utm_campaign=headlines&r=4bf001661e6fdd88d0cd7a5659ff9748&mod=mw_quote_news", "source_name": "GuruFocus", "published_at": "2026-07-17T20:10:53", "published_display": "17 Jul 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RGNX Stock Slides As $100M Offering And Legal Heat Hit", "summary": "REGENXBIO Inc. (RGNX) stock is down over 9% following news of a planned $100 million public offering of common stock and a pending investigation into its officers and directors over alleged misleading statements related to a gene therapy trial. The offering aims to fund its late-", "url": "https://stockstotrade.com/news/regenxbio-inc-rgnx-news-2026_07_17/", "source_name": "StocksToTrade", "published_at": "2026-07-17T18:09:29", "published_display": "17 Jul 2026 18:09", "sentiment": "negative", "sentiment_pct": 15, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Regenxbio Shares Fall on $100M Stock, Pre-Funded Warrant Offering", "summary": "Regenxbio (RGNX) announced a public offering of $100 million in common stock and pre-funded warrants. This financial move led to a significant 10% decline in the company's shares during after-hours trading. The offering includes standard stock and warrants, which can be exercised", "url": "https://www.moomoo.com/news/post/73153805/regenxbio-shares-fall-on-100m-stock-pre-funded-warrant-offering?futusource=news_newspage_recommend", "source_name": "Moomoo", "published_at": "2026-07-17T15:10:53", "published_display": "17 Jul 2026 15:10", "sentiment": "negative", "sentiment_pct": 29, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "REGENXBIO Raises $100M for Gene Therapy Pipeline", "summary": "REGENXBIO Inc. (Nasdaq: RGNX) announced a proposed underwritten public offering to raise $100 million for its gene therapy pipeline. This funding comes as the company advances multiple late-stage programs, including RGX-202 for Duchenne muscular dystrophy and RGX-121 for Hunter s", "url": "https://allsci.com/news/funding/public-equity-offerings/regenxbio-raises-usd-100m-amid-pivotal-year-for-gene-therapy-pipeline/", "source_name": "AllSci", "published_at": "2026-07-17T15:09:29", "published_display": "17 Jul 2026 15:09", "sentiment": "positive", "sentiment_pct": 63, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RGNX Stock Dips As Equity Offering And Litigation Raise Risk", "summary": "REGENXBIO Inc. (RGNX) stock experienced a significant dip due to a bearish sentiment following a planned $100M public offering of common stock and ongoing shareholder litigation. The equity offering aims to fund its late-stage gene therapy pipeline but introduces dilution, while ", "url": "https://timothysykes.com/news/regenxbio-inc-rgnx-news-2026_07_17/", "source_name": "timothysykes.com", "published_at": "2026-07-17T15:09:29", "published_display": "17 Jul 2026 15:09", "sentiment": "negative", "sentiment_pct": 30, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "REGENXBIO Prices $100 Million Public Offering", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/regenxbio-prices-100-million-public-112412501.html", "source_name": "MT Newswires", "published_at": "2026-07-17T11:24:12+00:00", "published_display": "17 Jul 2026 11:24", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "REGENXBIO Announces Pricing of Public Offering of Common Stock and Pre-funded Warrants", "summary": "REGENXBIO Inc. has announced the pricing of a public offering consisting of 10,003,889 shares of common stock at $9.00 per share and 1,111,111 pre-funded warrants at $8.9999 per warrant. The offering is expected to generate approximately $100.0 million in gross proceeds and is sl", "url": "https://www.prnewswire.com/news-releases/regenxbio-announces-pricing-of-public-offering-of-common-stock-and-pre-funded-warrants-302828273.html", "source_name": "PR Newswire", "published_at": "2026-07-17T11:09:29", "published_display": "17 Jul 2026 11:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Regenxbio prices $100m public offering at $9 per share", "summary": "REGENXBIO Inc. has priced an underwritten public offering of common stock and pre-funded warrants at $9 per share, aiming to raise approximately $100.0 million. This capital raise comes after a nearly 20% stock decline and a reported negative free cash flow of $236 million over t", "url": "https://www.investing.com/news/company-news/regenxbio-prices-100m-public-offering-at-9-per-share-93CH-4798047", "source_name": "Investing.com", "published_at": "2026-07-17T11:09:29", "published_display": "17 Jul 2026 11:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "REGENXBIO (RGNX) Launches $100M Public Offering at $9.00 per Sha", "summary": "REGENXBIO (RGNX) announced a $100 million public offering of common shares at $9.00 each and pre-funded warrants, aiming to raise capital for its gene therapy development despite a premarket stock decline. The company has a GF Score\u2122 of 60/100, showing moderate potential for long", "url": "https://www.gurufocus.com/news/8964529/regenxbio-rgnx-launches-100m-public-offering-at-900-per-share?utm_source=marketwatch&utm_medium=syndication&utm_medium=syndication&utm_campaign=headlines&utm_campaign=headlines&r=4bf001661e6fdd88d0cd7a5659ff9748&r=4bf001661e6fdd88d0cd7a5659ff9748&mod=mw_quote_news%3Futm_source%3Dmarketwatch&mod=mw_quote_news&mobile=true", "source_name": "GuruFocus", "published_at": "2026-07-17T07:00:00", "published_display": "17 Jul 2026 07:00", "sentiment": "negative", "sentiment_pct": 28, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "REGENXBIO (RGNX) Plans $100 Million Stock Offering Amid Market D", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxObE9xcGRucU5TT3lPMjB5Z1lRWDh1dDQ3QXBJeE43czREMmtuem42S3RHY0xwMGhUMDBfaTZjQzhNSjlBWURfVk05dnNqbEZwVHJjVFpqQ255T2VnbmxBUEV6SGJ6RElQZllKcHZuM0RnSmhDMk5TWVRDTnUzdDhnVlJYeWx6VTB2YkRnZngwRF9aWkwzOEVISVE0b1FiMWVPSzJTbFp3WjB4Zkh6Und3bnFlSnE?oc=5", "source_name": "GuruFocus", "published_at": "2026-07-17T00:56:15+00:00", "published_display": "17 Jul 2026 00:56", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RGNX Stock Slumps 15% After-Hours \u2014 What\u2019s Driving The Selloff?", "summary": "REGENXBIO Inc. (RGNX) shares dropped 15% after-hours following the announcement of a $100 million public stock offering, sparking dilution concerns among investors. The company, which specializes in gene therapies for rare diseases, has not specified how the new funds will be uti", "url": "https://www.tradingview.com/news/stocktwits:054b88e0e094b:0-rgnx-stock-slumps-15-after-hours-what-s-driving-the-selloff/", "source_name": "TradingView", "published_at": "2026-07-16T22:42:41", "published_display": "16 Jul 2026 22:42", "sentiment": "negative", "sentiment_pct": 29, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "REGENXBIO Announces Proposed $100 Million Public Stock Offering", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/regenxbio-announces-proposed-100-million-203808250.html", "source_name": "MT Newswires", "published_at": "2026-07-16T20:38:08+00:00", "published_display": "16 Jul 2026 20:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "REGENXBIO\u2019s Proposed $100M Stock Sale Has No Set Terms", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNaS1jWHNWQ0Q0dXAwZVQ0U1NpYVdEMUtEa19Yc2Q4TVBOVERscDgwYnpUTUViSUtUUTNFb0prb1lyMmRuRlhGa2ZLVW84TWt2cUhJV3NJYmJTY09ZUGJMSlNhV2JqMEF4MkFORzgwWXVVSk9qeXdxdl9WNVNVWHlUd1AtT3NrNDAtUU4yZnI2NlJfMDlkanJBME5TaENYM09sMy1YZWVOR1JoTzFCQ1E?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-16T20:26:00+00:00", "published_display": "16 Jul 2026 20:26", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "REGENXBIO (NASDAQ: RGNX) targets $100M stock sale to fund gene therapy", "summary": "REGENXBIO Inc. (NASDAQ: RGNX) plans a primary offering of $100 million in common stock to fund general corporate purposes, including clinical trials and pipeline development. The company anticipates receiving a $100 million milestone payment from AbbVie in July 2026 and expects i", "url": "https://www.stocktitan.net/sec-filings/RGNX/424b5-regenxbio-inc-prospectus-supplement-debt-securities-defcdb940e16.html", "source_name": "Stock Titan", "published_at": "2026-07-16T20:40:04", "published_display": "16 Jul 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "REGENXBIO files prospectus for up to $100M common stock offering", "summary": "REGENXBIO has filed a prospectus with the SEC for a common stock offering that could raise up to $100 million. The filing is a standard procedure that allows the company flexibility in future fundraising efforts. This move indicates potential plans to finance ongoing operations, ", "url": "https://www.msn.com/en-us/money/general/regenxbio-files-prospectus-for-up-to-100m-common-stock-offering/ar-AA284R7c?ocid=finance-verthp-feeds", "source_name": "MSN", "published_at": "2026-07-16T20:40:04", "published_display": "16 Jul 2026 20:40", "sentiment": "negative", "sentiment_pct": 39, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Regenxbio plans $100 million common stock offering", "summary": "REGENXBIO Inc. (NASDAQ:RGNX) announced a $100 million public offering of common stock, which will be underwritten by Morgan Stanley, J.P. Morgan, Leerink Partners, and Mizuho. The company, focused on gene therapy for rare and retinal diseases, is rapidly burning through cash, wit", "url": "https://www.investing.com/news/company-news/regenxbio-plans-100-million-common-stock-offering-93CH-4796837", "source_name": "Investing.com", "published_at": "2026-07-16T20:40:04", "published_display": "16 Jul 2026 20:40", "sentiment": "negative", "sentiment_pct": 38, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "REGENXBIO Announces Proposed Public Offering of Common Stock", "summary": "REGENXBIO Inc. announced its intention to offer and sell $100 million of its common stock in an underwritten public offering, contingent on market conditions. The company also plans to grant underwriters a 30-day option to purchase up to an additional 15% of the shares offered. M", "url": "https://www.prnewswire.com/news-releases/regenxbio-announces-proposed-public-offering-of-common-stock-302827988.html", "source_name": "PR Newswire", "published_at": "2026-07-16T20:40:04", "published_display": "16 Jul 2026 20:40", "sentiment": "negative", "sentiment_pct": 35, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RGNX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Reminds Stockholders of REGENXBIO Inc. to Contact the Firm Today!", "summary": "Bronstein, Gewirtz and Grossman, LLC has filed a class action lawsuit against REGENXBIO Inc. (NASDAQ: RGNX) and its officers. The lawsuit alleges that REGENXBIO made false and misleading statements regarding its gene therapy RGX\u2011111 for treating Hurler syndrome. Investors who pur", "url": "https://natlawreview.com/press-releases/rgnx-investor-alert-bronstein-gewirtz-and-grossman-llc-reminds-1", "source_name": "The National Law Review", "published_at": "2026-07-15T08:11:16", "published_display": "15 Jul 2026 08:11", "sentiment": "negative", "sentiment_pct": 9, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Regenxbio | 8-K: Current report", "summary": "This document is an 8-K current report filed by Regenxbio. It is a standard regulatory filing used to announce material events that shareholders should know about.", "url": "https://www.moomoo.com/news/notice/307458163/regenxbio-8-k-current-report", "source_name": "Moomoo", "published_at": "2026-07-12T19:40:20", "published_display": "12 Jul 2026 19:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RegenxBio doses first patient in phase 2b/3 trial for DR", "summary": "RegenxBio has dosed the first patient in its phase 2b/3 NAAVIGATE trial for surabgene lomparvovec (sura-vec, ABBV-RGX-314) for diabetic retinopathy (DR) using suprachoroidal delivery. This gene therapy, developed in partnership with AbbVie, utilizes RegenxBio's proprietary NAV Te", "url": "https://glance.eyesoneyecare.com/stories/2026-07-10/regenxbio-doses-first-patient-in-phase-2b-3-trial-for-dr/", "source_name": "Eyes On Eyecare", "published_at": "2026-07-10T17:40:10", "published_display": "10 Jul 2026 17:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "(RGNX) Movement as an Input in Quant Signal Sets", "summary": "This article from Stock Traders Daily analyzes Regenxbio Inc. (NASDAQ: RGNX) using AI models, identifying strong near and mid-term sentiment but a weak long-term outlook. It provides specific institutional trading strategies (Position, Momentum Breakout, Risk Hedging) with entry ", "url": "https://news.stocktradersdaily.com/news_release/98/RGNX_Movement_as_an_Input_in_Quant_Signal_Sets_070926044001_1783629601.html", "source_name": "Stock Traders Daily", "published_at": "2026-07-09T16:10:49", "published_display": "09 Jul 2026 16:10", "sentiment": "positive", "sentiment_pct": 66, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Regenxbio Inc outlines gene therapy pipeline as Nasdaq-listed biotech stays focused on long-term gro", "summary": "Regenxbio Inc. is a Nasdaq-listed gene therapy company focusing on long-term growth through its clinical pipeline and licensing model in rare diseases and ophthalmology. The company utilizes proprietary AAV vector technology to develop gene therapies designed for durable treatmen", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/regenxbio-inc-outlines-gene-therapy-pipeline-as-nasdaq-listed-biotech/69715973", "source_name": "AD HOC NEWS", "published_at": "2026-07-07T16:42:17", "published_display": "07 Jul 2026 16:42", "sentiment": "positive", "sentiment_pct": 81, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Regenxbio Insider Sold Shares Worth $688,756, According to a Recent SEC Filing", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/regenxbio-insider-sold-shares-worth-082648885.html", "source_name": "MT Newswires", "published_at": "2026-07-02T08:26:48+00:00", "published_display": "02 Jul 2026 08:26", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Proposed 43,206-share sale for RGNX (NASDAQ: RGNX) tied to option exercise", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxQTXF6QmJDTzEwU2l3UmszS01QOElES1ZyNWNoYkIzRUNMbDNfbWR2eWp3OWp5NTFYSWNFaEQ2ekcxQ2xTM0EyS1pGTzQ1TmRVa0FSYl81RHZScXZzY2VWUno4cE1CaFRoYlRtNTVHUzM5aHJTV3NUbzRrSUNnR24wTXduLTRyN20taEIyOUdLeWRHM3ZX?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-01T07:00:00+00:00", "published_display": "01 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "REGENXBIO's Trial of Surabgene Lomparvovec in Diabetic Retinopathy Doses First Patient", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/regenxbio-apos-trial-surabgene-lomparvovec-120939541.html", "source_name": "MT Newswires", "published_at": "2026-06-29T12:09:39+00:00", "published_display": "29 Jun 2026 12:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "REGENXBIO doses first patient in eye-disease gene therapy trial", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxNM1Z4dUh0U1R1MmNaYW9zd3VlVWF6QjVQb3BsVGVzMG1wa19UTTBISk9LaU4ycE5halJsZ011WTE2dmQ2LWtyQkpweXpKOWpMYzZkeUFvVVRnSlA2TDRnT19hajJsZnplaUh3eUFxcHlNZWY5RmIxQWFKeWp2ZklucEdmdjczanVlSGVtRmJvVWcyTWZTaWlJY1JZMHczT182Vlk5ZWtvZW9TNDdzSFBpSXlpUV84SFBvY2F3aXBMYw?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-29T07:00:00+00:00", "published_display": "29 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "REGENXBIO clears key Duchenne study step, aims for BLA filing in Q3", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxQNUpwRjNhRm5ZUWpNN0dRcG9FeEhYcjluNDR4SG1MWUppUDNESTZQeGVrX0F0THU3ejk3VzZDTG9BLUtJT2RPS3dnQmlFU1lNanRSQlNQZkNqdmZuVWFySk1PWjd5WHpRWjdyRmJHZUIteFFGWTBUWktNUUhybHQ1d2NZQ04xdURjUGsxRFI1cWIyM25yVTZWQVZkX1hRWEtrdnRBMkpmN29rYTBWaFcwT09jNExWdm01T0xadVFZSQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-24T07:00:00+00:00", "published_display": "24 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H.C. Wainwright reiterates Regenxbio stock rating on FDA pathway", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxOR3NhbDQyTEZ4eUI0cG9ndkswZmhBTi1jYktuSzJzZFd5eEcza0tHTm5GQ0UzallVaE9jaTJoQlF5WTVZV1JjcXdRTWNmRXRUXzJDb2xBSS0wQTNmaGNpYjd0el9KNnVMdjN1ZlVCMnE1SGdTbVVFV1ctSUNIV19Bd1NGb2FLb0pEcTlBRWNpY043OTc5SWYycjlnUXFWS2lPc1Zkb01KdmtsT1hVbk9pWWdybU5lNFg1NDg4d0N4aw?oc=5", "source_name": "Investing.com", "published_at": "2026-06-23T07:00:00+00:00", "published_display": "23 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "REGENXBIO gets FDA path to resubmit NAVSUNLI for MPS II", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxOcGxveGdJWUp6RGNwS1hRemRZaTdSNmViM0RDMF90NHlSWWxOZ0I3a1dFdlJEWFNpelZyWm1NdTVDd2lEaVNwWTlyTk5DeTd6STJCcERUNlAzS0JGcFpCejlrcC1mbVNuVlhrcnZPRFo0UFlWWU1SeHN6NHUxMDB4ZGpqQU5MdWE4U2hqSWdNNWN2TzdiSl9xUUxMSTRKS2czNWFfRExjTFVuT2EtWnlocUlDTQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-22T07:00:00+00:00", "published_display": "22 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RGNX Retail Investors See Hope As FDA Reopens Door For Regenxbio\u2019s Hunter Syndrome Therapy", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwgFBVV95cUxPTGVWVkt4b3NZMFlvbHcyc3VJNE5qWkE0UGdyWjRRV0ZYVk1DSm00ckotd1VIQ25qVlZhZm9lSHJNU3diTFBPaHRBZzdSRXpiTGFUaHJoVFJSU1hLcEZVZkhaNjc4a0szWFBFN1lfNk1Zb2JKWTYyN09ocEw2YnMzZmZXUDhrT0pCWWtoU3JRVlZXUDhBWE4zVGpiZzB5ZkN5Z0ZPaFVuemZHdk5CSjQzRUVtemJORXFGWXpWa2RWQVhOdw?oc=5", "source_name": "Stocktwits", "published_at": "2026-06-22T07:00:00+00:00", "published_display": "22 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "JPMorgan affiliates report 4.4% stake in REGENXBIO (RGNX) in 13G/A", "summary": "", "url": "https://news.google.com/rss/articles/CBMixwFBVV95cUxQOW0tSFNtTFhIYnpTRXRxVE9GVkFwekFqRldVT244ZWxacWxoMlhKeW5UOG10YWFLemVrZ05VeVZncjByZFRYU3BlNk41Q0FFOUlxWUN1LTdsN3N1Q1ktSVAxNThra1kxY3h6MXdhdnc0N1M4N0ZjR1Z5dkgxVTloeFc0TXI1czhiQ1pNQWkwaU1hbmRQZDQxMGQ1ZXNiVXRTaklrSmNhdXdpaWlwXzFiOGVJV0tYaG42b2NfcjdZYTIzTEJQODZN?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-04T07:00:00+00:00", "published_display": "04 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Before Buying Regenxbio Inc (RGNX) Stock, Check Out the Cash Runway", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxQX2c4M0RLM2NtTnBJM1AzRGdMOUROUkR4SURJbW96YjVESTlLVWNYV3VHNTRXUmFjc3hfMXNUSkhIU2hyYkJkb3QwYzFrWWdaaGhrSi1nZV9paEFRSFpURS1udEQ0THlESkpvakw4RXN4X2pxTzMxRHpPTldEQkFQaVBvSWNyVmkzMkFVc2s4MnZtcVFJcVFseXdvQVZua2xrNWc?oc=5", "source_name": "Market source", "published_at": "2026-05-20T07:00:00+00:00", "published_display": "20 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "StockWatch: Regenxbio Tumbles Despite Positive Pivotal Data for DMD Gene Therapy Candidate", "summary": "", "url": "https://news.google.com/rss/articles/CBMi4AFBVV95cUxPZkp0VzdkNVVCV0NTejgyeUs5emJBczlDcmZNRDZaSzQ2YXFuQ1diNnpLSE9oMmY0UHZSNllUY25rX0huN3ZNZEZUY2JUUDZ2Y2NCczJ1MlJLZ2RNVDU3OU1TM3RmVjhmQWxlcXppM3FpVFltTmxKTkxuWU8waVRON01IOTJoSHlLSW1BMDFvNjItZDVmTjF3N29MVmpaQlpyY0ZVUHdFSWhuTGtLNFY4RlFnVUFMaHItbEtpZzJHV1BkT1B5bVBmSmdwYmtxbmJTZ2RPTkoyRm01Y2hxUkE4Qg?oc=5", "source_name": "Genetic Engineering and Biotechnology News", "published_at": "2026-05-17T07:00:00+00:00", "published_display": "17 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Goldman Sachs lowers Regenxbio stock price target on regulatory uncertainty", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0AFBVV95cUxQMUlpamVaN0x0TkVqTFhIWHNubWJQa050VXJZZWU2T2p0bVhJb1pCT2lERTFIclFlZ0tzMFZVRl9vcnAtOGt5TE5mZFdHUjdZaEFGeDhYdVRkaV9HU0NtSGNsTzhTVk1CRFlIS2RldWZieVlNalpOdXd3Tmd2WWp0VVZydlZJQktsMVZPUzZTWTEtUjZEUE5ubkg4bjlxQm9tWmN3LWpZVlc1STRkeVJKdkRDV0EwSXVPcGY0YmdmVW1lNE1WUFpwTmZaSGxaY3dU?oc=5", "source_name": "Investing.com", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Regenxbio (RGNX) Q1 Loss Deepens And Reinforces Bearish Cash Runway Concerns", "summary": "", "url": "https://news.google.com/rss/articles/CBMi2wFBVV95cUxNekF3REFEdFZMa0RTMy1jWHMweEQzTF9TSFd1eW5paGJ1SGpUUnNlVXhhTTV1LWhvWXQwZ0VTLUZxa2ZDWDdqYlhvQk9ra3JNeGV5RkgtSHQzODJ4WUkyeEFyZEYyaFk0LUlsTzhpam5OZzlwdVdlTW5saWphVVZzdm82Ri1DMnVCdVd0MXBMZXlMZmhfdmJVNVJRX2dfODJxSGw1Qi1QcUdBUVd2emxrU01FUUVoX0RNUF8xRDNBSXZONGZ1bUlJbW52eFRQNkFJRUlLODV2V2J4ZzjSAeABQVVfeXFMTmVtNTVFUlprT3o0NERoaVd3V2FZa0x4TGN2eG9qQm1FX2RGLVVfZENYd2VvR2ZDRXc1b3Zfb01iVkEtS19kV1pyRFZYWThOSWJyUWczTWF2U2NpM05rU2lrMVdveXRuMmJxOTF1NHFJLTZnOUZLekpodkJKTTFtQUpFaFFHb2Y1M1pJbG5RU1BHdEUxWW4zR1R0X2lXRjNrNlptVEFYZF9QWVQ2ejgta3VkU0EyQ2g4VngxU21yQ0lOWUZyZENnMTNlRG1YT0FYelFwTTdjdEo3eEh1VkxBQU0?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 18, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why is Regenxbio stock plunging today?", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxPRnh6MTZXYzlRQk1BVEZJVmZMNnJ0ak02TVBRU1piT0dScHNYRFJkQXpfR3o4WGpqcVZZaU5ybEtmNUItOVVqdTctUGo5bzAzaEFUYjFkLXU4QWYxSEZxNUYzOTlXNE03ajJOWHZwbzhjeVhvblZlU3N1dEpxSjB4bEpXbTFnSFdlYW1iSGlQTGRfZnFDcDBrMU54amFlUG5E?oc=5", "source_name": "Investing.com", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Duchenne gene therapy clears Phase III goal as REGENXBIO posts $90M loss", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxNVDdZQnB1WU83Y21rdDdyeDJXQTBWdUpYS0tTU1ROV3FCdU5MV0w2bnZjMGtBMk9uaEROUW81SElSSmtDU1JaeXRuN3kza0txeHlMajE2NHM0c3Uzc2FkTERxZllzdC1NQm5wUUR5WFhLT2Y3S2ZCUzFROVlkR3FVTnJ1R1E4SWwzdFBBMTlQNjVtOVpqMHhfdFczN3M5TGlLdjRjV0gxaDE3QUZfVWQ1OVl6aw?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sarepta Hits Fresh Hurdle As Court Revives Patent Lawsuit With Regenxbio Over Muscular Disorder Therapy", "summary": "", "url": "https://news.google.com/rss/articles/CBMi-wFBVV95cUxPbnpwWDJhbVdjOTZVODduRkNOVVAxYVBRUXUtY200cUNMMzV1U2dWSEV6NThyMTFmSDRWRHRuWUdMZ2Z3MWx2NU14YV9lak03SDNERnVacjFNR092S2xsTzdqT1VNaXFfdi1POVBIbXpaUThINkc4S3lKVXlLT1dGLU5qbG1ZQ05DSFVfMXlLQzRDWEY3dTlaaWxaQUJ4ZHVxdUxhd1VOOFlBNVhTdW1qVEZXWEZncmM0Y01heGRHM2VDb0ZfeHg3d1M3eTJJaFRfR09uV0xPaUhKRHp2bVNIOHZEektibVJqQ19yRFFTSnZ0ZXh5UXh0S0ZWYw?oc=5", "source_name": "Stocktwits", "published_at": "2026-02-20T22:04:27+00:00", "published_display": "20 Feb 2026 22:04", "sentiment": "negative", "sentiment_pct": 34, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Regenxbio Stock Still Has Over 300% Upside Despite FDA Pushback On Hunter Syndrome Drug: Clear Street", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1AFBVV95cUxPbV9MNHF1YWpfZlpoRmpLVjRrWWFWQXNSOUdTWEhuajhFa2haY3lIUHJjSkhuVm03WlpmdDVobmtoU2ZDNV9Qa21CRE1VdWhaTDBfeWl6Wjg3TG5tV2trTGc0ODBBcEt2eWpWWHprREx4a3UwVlBUTHVXanBqRjRhZ2xwbEJLSXp2dUJXZlFFNFBzemJkUUdkYzJsbmNPY09ISjhVeENtZFVGa0JEYVpLWkRSaW1RLUVTNFc3MkRXaElDNk1wNE0ycmdaMzk1TjljZVN1bg?oc=5", "source_name": "Stocktwits", "published_at": "2026-02-09T08:00:00+00:00", "published_display": "09 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "US FDA declines to approve Regenxbio's gene therapy for rare disease", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwgFBVV95cUxQOERkNXNGX05jeWdQNWFrTFpCcW0yWDFKUlZLaFFRX2J0UHpxRTk4SVdaOUdlOS11WUF3Q2xHOEloU2JvUUFvUGhJb283TmV2Tm9SRkdpRTNNSzRpdVNZU3E4MG5IdDl5Zk9USTR3X1JFZTlXTFlBR2NKZVBvM28yVjcwOVZZdjBtTDhZMENkUmVldm9vclAxNFg4UmQ0WWdTWnFLR3NzVGRuZlRVTmNYVjlkdW1LcHg3MF94V0kzdWpXQQ?oc=5", "source_name": "Reuters", "published_at": "2026-02-09T08:00:00+00:00", "published_display": "09 Feb 2026 08:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "REGENXBIO Inc. (NASDAQ:RGNX) Looks Inexpensive After Falling 28% But Perhaps Not Attractive Enough", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-02-06T08:00:00+00:00", "published_display": "06 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T07:00:00+00:00", "published_display": "13 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 101, "total_relevant": 62, "sentiment_summary": {"positive": 9, "negative": 20, "neutral": 33, "score": 45, "total": 62, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 79, "events": [{"event": "general", "label": "Market update", "weight": 18.5, "count": 33}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 4.75, "count": 8}, {"event": "earnings", "label": "Earnings", "weight": 4.26, "count": 10}, {"event": "liquidity", "label": "Balance sheet", "weight": 2.75, "count": 5}, {"event": "guidance", "label": "Guidance", "weight": 1.1, "count": 2}, {"event": "deals", "label": "Deals and strategy", "weight": 1.1, "count": 2}], "positive_events": 9, "negative_events": 20}, "market_context": {"has_market_context": true, "latest_close": 9.89, "latest_week": "2026-07-17", "one_week_move": -29.1, "four_week_move": 26.8, "twelve_week_move": 12.9, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": 1.200288, "market_dynamics_buy_signal": false, "relative_strength": -13.086255, "fair_value_gap": -17.8, "fair_value_label": "Near fair-value range", "fair_value_tone": "neutral", "expectation_direction": "undecided", "expectation_probability": 46.3366, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-29.1% over one week, +26.8% over four weeks, trend inactive, and near fair-value range."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "negative", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 64, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Stock Titan", "count": 11}, {"label": "Market source", "count": 7}, {"label": "Investing.com", "count": 5}, {"label": "MT Newswires", "count": 4}, {"label": "simplywall.st", "count": 4}, {"label": "PR Newswire", "count": 3}, {"label": "GuruFocus", "count": 3}, {"label": "Stocktwits", "count": 3}], "tiers": [{"label": "Direct company coverage", "count": 53}, {"label": "Industry context", "count": 9}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 33}, {"label": "Earnings", "count": 10}, {"label": "Regulatory and legal", "count": 8}, {"label": "Balance sheet", "count": 5}, {"label": "Guidance", "count": 2}, {"label": "Deals and strategy", "count": 2}, {"label": "Analyst action", "count": 2}]}, "insights": [{"label": "Weighted tone", "value": "45/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "negative", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "79/100 classification confidence."}, {"label": "Company focus", "value": "53", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "2", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "-29.1% over one week, +26.8% over four weeks, trend inactive, and near fair-value range."}, {"label": "Latest direct headline", "value": "Negative", "tone": "negative", "text": "Lawsuit alleges Regenxbio misled investors on gene therapy trial results for Hurler Syndrome."}], "updated_at": "2026-07-23T08:49:08.245476+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}